Orexo AB - Company Profile

Powered by

All the data and insights you need on Orexo AB in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Orexo AB Strategy Report

  • Understand Orexo AB position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Orexo AB: Overview

Select Item

Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company’s commercial product portfolio consists of Abstral, Edluar, and Zubsolv. The company develops its products based on its proprietary drug delivery technology, namely, sublingual tablet technology. The sublingual tablet rapidly disintegrates and dissolves, allowing the medicine to be directly absorbed into the bloodstream through the mucous membrane. It also carries out the industrial-scale production of pharmaceutical products. Orexo collaborates with various pharmaceutical companies to advance and commercialize its products. Orexo is headquartered in Uppsala, Sweden.

 Gain a 360-degree view of Orexo AB and make more informed decisions for your business Gain a 360-degree view of Orexo AB and make more informed decisions for your business Find out more
Headquarters Sweden
Address Rapsgatan 7e, Uppsala, 75105
Website orexo.se
Telephone 46 18 7808800
No of Employees 116
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange ORX (STO)
Revenue (2022) $60.2M 2.3% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 27.8% (2022 vs 2021)
Market Cap* $55.6M
Net Profit Margin (2022) XYZ 29.4% (2022 vs 2021)
* As of and is in US$
View Orexo AB financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Orexo AB premium industry data and analytics

40+

Clinical Trials

Determine Orexo AB go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Catalyst Calendar

Proactively evaluate Orexo AB’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Pipeline Drugs

Identify which of Orexo AB’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

8

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

6

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Sales & Consensus Forecasts

Understand the current and future drug revenue for Orexo AB and assess market opportunity for new entrants with patient population 8-year forecasts.

1

Marketed Drugs

Understand Orexo AB’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Orexo AB’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Zubsolv - Opioid Dependence Deprexis
Edluar - Short-Term Insomnia Vorvida
Abstral - Cancer Pain Abstral
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Orexo AB portfolio and identify potential areas for collaboration Understand Orexo AB portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Orexo AB Indivior Plc Calliditas Therapeutics AB Hansa Biopharma AB SpectraCure AB
Headquarters Sweden United Kingdom Sweden Sweden Sweden
City Uppsala Slough Stockholm Lund Lund
State/Province - Berkshire Stockholm - -
No. of Employees 116 1,051 181 168 16
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
James Noble Chairman Executive Board 2020 64
Nikolaj Sorensen Chief Executive Officer; President Senior Management 2013 51
Fredrik Jarrsten Executive Vice President; Chief Financial Officer Senior Management 2022 -
Edward Kim, M.D Chief Medical Officer Senior Management 2022 -
Cecilia Coupland Senior Vice President; Head - Operations Senior Management 2019 47
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Orexo AB key executives to enhance your sales strategy Gain insight into Orexo AB key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward